D. George

Efficacy and Safety Evaluation of Human Reovirus Type 3 in Immunocompetent Animals

K. Fonseca, S. Nishikawa, B. Thompson, 2004, Clinical Cancer Research.

Efficacy and Safety Evaluation of Human Reovirus Type 3 in Immunocompetent Animals: Racine and Nonhuman Primates

K. Fonseca, S. Nishikawa, B. Thompson, 2004 .

Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology

Heather L. Mulder, Michael C. Rusch, R. Wilson, 2016, Acta Neuropathologica.

A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.

B. Thompson, J. Markert, G. Roldan, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Leptomeningeal Disease from Oligodendroglioma: Clinical and Molecular Analysis

G. Roldan, J. Easaw, P. Forsyth, 2008, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics

A. Narendran, D. Strother, D. Bernoux, 2008, Journal of Neuro-Oncology.

Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer

K. Norman, D. Stewart, X. Lun, 2004, Gene Therapy.